As these cells migrate to nearby lymph nodes, they continue to elaborate surface signals that will optimize T cell activation. By the time  DC cells reaches their destination (around a day) their cell surface is fully loaded with displayed tumor antigens and co-stimulatory molecules ready to activate an army of T cells, each platoon sensitized to one of the multitude of possible antigens generated from the autologous tumor cell preparation.  The T cells proliferate and promote a long-term adaptive immune response, hunting down and destroying cells that display tumor antigens anywhere they find them, while remaining tolerant to non-tumor “self” antigens.

In the case of glioblastoma, the blood-brain-barrier remains open for up to a week after surgery, allowing time for the initial wave of an adaptive immune response to infiltrate and attack any residual tumor.

As an investigational therapeutic vaccine, to date there is no evidence of IMV-001 inducing a systemic inflammatory response. The IMV-001 investigational vaccination technique is simultaneously universally applicable to other solid tumors, and patient-specific-- a massively scalable way to potentially target and provide lasting resistance to even the most difficult-to-treat cancers, including:

Malignant Gliomas

Here’s how we do it:

Step 1:  Patient Cell Harvest, Treatment, and Implant

Step 2:  Immunogenic Cell Death, Patient-Specific Antigens, Innate Immune System Activation

Step 3:  Long-term Adaptive Immune Activation and Response